Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking & Finance Review

Company

    GBAF Logo
    • About Us
    • Profile
    • Wealth
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2025 GBAF Publications Ltd - All Rights Reserved.

    ;
    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Top Stories

    EU to propose easing medicines flow from Britain to Northern Ireland

    EU to propose easing medicines flow from Britain to Northern Ireland

    Published by maria gbaf

    Posted on December 17, 2021

    Featured image for article about Top Stories

    BRUSSELS (Reuters) – The European Commission is due to set out on Friday legal changes to ease the transport of medicines from Britain to Northern Ireland, a move that could relieve EU-UK tensions over the British province’s future after Brexit.

    The flow of medicines is currently unimpeded, but set to change when a grace period expires at the end of the year.

    Then British operators would need to move regulatory compliance and logistics and testing facilities to the European Union or to Northern Ireland, which is part of the United Kingdom but within the EU single market for goods.

    The cost of the move could result in certain companies deciding to stop supplying medicines to Northern Ireland, exacerbating trading problems the province is facing after Brexit.

    The EU executive is set to propose an exception to existing law to allow compliance and logistics to be located in the British mainland.

    The change could also benefit other smaller markets – Cyprus, Ireland and Malta – that have traditionally received certain medicines from Britain.

    A further change, solely for Northern Ireland, could allow marketing of drugs in Northern Ireland after they have been authorised by the British medicines regulator, but before approval from the European Medicines Agency.

    This move could, for example, affect new cancer treatments.

    The Commission declined to comment on the substance of any proposals.

    The changes, which would require approval by the European Parliament and EU governments during 2022, do not represent a formal agreement with Britain on the subject.

    It has advocated removing medicines entirely from the protocol that sets out the post-Brexit trading arrangements of Northern Ireland and a renegotiation of the protocol itself.

    The EU has offered a package of measures https://www.reuters.com/world/europe/whats-eu-plan-future-britain-to-nireland-trade-2021-10-13 designed to ease transit of goods to Northern Ireland.

    (Reporting by Philip Blenkinsop; Editing by Alison Williams)

    BRUSSELS (Reuters) – The European Commission is due to set out on Friday legal changes to ease the transport of medicines from Britain to Northern Ireland, a move that could relieve EU-UK tensions over the British province’s future after Brexit.

    The flow of medicines is currently unimpeded, but set to change when a grace period expires at the end of the year.

    Then British operators would need to move regulatory compliance and logistics and testing facilities to the European Union or to Northern Ireland, which is part of the United Kingdom but within the EU single market for goods.

    The cost of the move could result in certain companies deciding to stop supplying medicines to Northern Ireland, exacerbating trading problems the province is facing after Brexit.

    The EU executive is set to propose an exception to existing law to allow compliance and logistics to be located in the British mainland.

    The change could also benefit other smaller markets – Cyprus, Ireland and Malta – that have traditionally received certain medicines from Britain.

    A further change, solely for Northern Ireland, could allow marketing of drugs in Northern Ireland after they have been authorised by the British medicines regulator, but before approval from the European Medicines Agency.

    This move could, for example, affect new cancer treatments.

    The Commission declined to comment on the substance of any proposals.

    The changes, which would require approval by the European Parliament and EU governments during 2022, do not represent a formal agreement with Britain on the subject.

    It has advocated removing medicines entirely from the protocol that sets out the post-Brexit trading arrangements of Northern Ireland and a renegotiation of the protocol itself.

    The EU has offered a package of measures https://www.reuters.com/world/europe/whats-eu-plan-future-britain-to-nireland-trade-2021-10-13 designed to ease transit of goods to Northern Ireland.

    (Reporting by Philip Blenkinsop; Editing by Alison Williams)

    Related Posts
    ELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONESELECTIVA MARKS A LANDMARK FIRST YEAR WITH MAJOR SENIOR APPOINTMENTS AND EXPANSION MILESTONES
    Hebbia Processes One Billion Pages as Financial Institutions Deploy AI Infrastructure at Unprecedented ScaleHebbia Processes One Billion Pages as Financial Institutions Deploy AI Infrastructure at Unprecedented Scale
    Beyond Governance Fatigue: Making ESG Integration Work in Financial MarketsBeyond Governance Fatigue: Making ESG Integration Work in Financial Markets

    Why waste money on news and opinions when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe